OMEROS CORP
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net income (loss) | $69,292 | $(58,884) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,510 | 4,518 |
| Amortization of discount and issuance costs on 2026 Notes and 2029 Notes | 2,897 | 988 |
| Loss on early extinguishment of 2029 Notes | 1,896 | — |
| Depreciation and amortization | 432 | 489 |
| Loss on early extinguishment of 2026 Notes | — | 2,968 |
| Remeasurement on fair value of financial instruments | (84,593) | (8,142) |
| Non-cash interest on OMIDRIA contract royalty asset | (6,195) | (7,839) |
| Remeasurement of OMIDRIA contract royalty asset | (5,191) | 2,981 |
| Non-cash interest remeasurement on OMIDRIA royalty obligation | (853) | (11,878) |
| Amortization of premium and issuance costs on term debt | — | (3,214) |
| Changes in operating assets and liabilities: | ||
| OMIDRIA contract royalty asset | 16,694 | 15,251 |
| Prepaid expenses and other | 1,737 | 315 |
| Receivables | (10,384) | 1,463 |
| Inventory | (842) | — |
| Accounts payable and accrued expense | 1,243 | 3,205 |
| Net cash used in operating activities | (10,357) | (57,779) |
| Investing activities: | ||
| Proceeds from the sale and maturities of investments | 43,650 | 61,000 |
| Purchases of investments | (11,471) | (1,108) |
| Purchases of property and equipment | (45) | (54) |
| Net cash provided by investing activities | 32,134 | 59,838 |
| Financing activities: | ||
| Exercise of stock options | 11,066 | 88 |
| Repayment of 2026 Notes | (17,077) | — |
| Principal payments on OMIDRIA royalty obligation | (9,132) | (6,701) |
| Repurchases of common stock | (9,878) | — |
| Net share settlement of equity awards | (4,108) | — |
| Payments on finance lease obligations | (320) | (392) |
| Proceeds from issuance of common stock from the ATM facility, net | — | 6,287 |
| Payment of debt issuance costs related to 2029 Notes | — | (2,837) |
| Net cash used in financing activities | (29,449) | (3,555) |
| Net increase (decrease) in cash and cash equivalents | (7,672) | (1,496) |
| Cash and cash equivalents at beginning of period | 9,660 | 3,400 |
| Cash and cash equivalents at end of period | $1,988 | $1,904 |
| Supplemental cash flow information | ||
| Cash paid for interest | $11,492 | $18,697 |
| Cash paid for income taxes, net | $501 | $182 |
| Exchange of 2026 Notes for 2029 Notes | $— | $70,785 |
| Exchange of 2026 Notes for share-settled liability | $— | $8,085 |
| Exchange of 2026 Notes for common stock | $— | $1,915 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.